25 results
10-Q
2024 Q1
NAMS
NewAmsterdam Pharma Company NV
8 May 24
Quarterly report
4:30pm
and requirements, which could cause significant liability for us or harm our reputation.
We are exposed to the risk that our employees, independent … sanctions and serious harm to our reputation. We have adopted a code of business conduct and ethics and train our employees on these topics
10-K
2023 FY
NAMS
NewAmsterdam Pharma Company NV
28 Feb 24
Annual report
8:00am
activities, including noncompliance with regulatory standards and requirements, which could cause significant liability for us or harm our reputation.
We … in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. We have adopted a code of business conduct
10-K
2023 FY
EX-10.8
NAMS
NewAmsterdam Pharma Company NV
28 Feb 24
Annual report
8:00am
and reputation or other objective reasons.
10.2.Before commencing any ancillary activities, the Employee is obliged to inform the Employer in writing … to the Employer or (ii) has, or could reasonably be expected to have, an adverse impact on the business and/or reputation of the Employer;
b.the
10-K
2023 FY
EX-10.4
NAMS
NewAmsterdam Pharma Company NV
28 Feb 24
Annual report
8:00am
on the business and/or reputation of the Company and/or any Subsidiary;
Subsidiary on the other;
f.except with respect to U.S. Participants, conduct
424B3
NAMS
NewAmsterdam Pharma Company NV
15 Aug 23
Prospectus supplement
4:52pm
, which could cause significant liability for us or harm our reputation.
We are exposed to the risk that our employees, independent contractors … and serious harm to our reputation. We have adopted a code of business conduct and ethics, but it is not always possible to identify and deter misconduct
POS AM
65ww9d
7 Aug 23
Prospectus update (post-effective amendment)
7:56am
6-K
EX-99.2
xz3w8rbbf1uigezsawf
7 Aug 23
Research and development expenses
7:24am
424B3
g5w3goll xfn8txv
8 Jun 23
Prospectus supplement
5:01pm
424B3
9s1ujerel 6f7vm
6 Jun 23
Prospectus supplement
4:20pm
424B3
jhomotk98x 54aoqv07g
25 Apr 23
Prospectus supplement
8:14am
POS AM
ddihd7sd96cnbn4l5qi
17 Apr 23
Prospectus update (post-effective amendment)
9:09am
S-8
EX-99.1
ylf1cwd 9d73ynmhl7bk
31 Mar 23
Registration of securities for employees
7:36am
S-8
EX-99.2
sxuyae qu
31 Mar 23
Registration of securities for employees
7:36am
F-1
uyuxw c0ok4b1f5
19 Dec 22
Registration statement (foreign)
6:22pm
F-1
EX-10.13
tv892ylu2
19 Dec 22
Registration statement (foreign)
6:22pm
F-1
EX-10.15
iwch20o em15
19 Dec 22
Registration statement (foreign)
6:22pm
6-K
EX-10.1
j8v192kuv1m
19 Dec 22
NewAmsterdam Announces Appointment of David Topper as Chief Financial Officer
4:23pm
424B3
66p xjm08
18 Oct 22
Prospectus supplement
4:41pm
F-4/A
b8u88r hh
13 Oct 22
Registration of securities (foreign) (amended)
5:18pm